FourThought Financial Partners LLC Has $26.50 Million Stock Position in Astrazeneca Plc $AZN

FourThought Financial Partners LLC boosted its position in Astrazeneca Plc (NYSE:AZN) by 2.7% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 150,996 shares of the company’s stock after purchasing an additional 3,986 shares during the period. Astrazeneca makes up approximately 2.2% of FourThought Financial Partners LLC’s holdings, making the stock its 5th biggest position. FourThought Financial Partners LLC’s holdings in Astrazeneca were worth $26,500,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in AZN. Triumph Capital Management bought a new stake in Astrazeneca in the third quarter valued at $25,000. Bangor Savings Bank grew its holdings in shares of Astrazeneca by 102.7% during the fourth quarter. Bangor Savings Bank now owns 304 shares of the company’s stock valued at $28,000 after buying an additional 154 shares during the last quarter. Eagle Bay Advisors LLC acquired a new stake in shares of Astrazeneca in the 4th quarter worth about $30,000. Rakuten Investment Management Inc. bought a new position in Astrazeneca in the 3rd quarter valued at about $31,000. Finally, YANKCOM Partnership acquired a new position in Astrazeneca during the 4th quarter valued at about $31,000. 20.35% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have commented on AZN. TD Cowen reissued a “buy” rating on shares of Astrazeneca in a report on Wednesday, March 18th. Sanford C. Bernstein reiterated a “buy” rating on shares of Astrazeneca in a research note on Monday, May 4th. Barclays raised Astrazeneca from a “neutral” rating to a “buy” rating in a research report on Wednesday, April 29th. Wall Street Zen raised Astrazeneca from a “hold” rating to a “buy” rating in a research report on Saturday, May 2nd. Finally, Jefferies Financial Group reaffirmed a “buy” rating on shares of Astrazeneca in a research report on Wednesday, May 13th. Twelve equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Astrazeneca has a consensus rating of “Moderate Buy” and a consensus target price of $205.33.

Astrazeneca Trading Up 1.5%

Shares of AZN opened at $187.50 on Thursday. The business’s 50-day moving average price is $191.82 and its 200-day moving average price is $182.58. The company has a quick ratio of 0.71, a current ratio of 0.91 and a debt-to-equity ratio of 0.52. Astrazeneca Plc has a twelve month low of $137.23 and a twelve month high of $212.71. The stock has a market cap of $290.79 billion, a PE ratio of 28.15, a P/E/G ratio of 1.52 and a beta of 0.26.

Astrazeneca (NYSE:AZN) last announced its quarterly earnings results on Wednesday, April 29th. The company reported $2.58 EPS for the quarter, beating the consensus estimate of $2.52 by $0.06. The firm had revenue of $15.29 billion during the quarter, compared to the consensus estimate of $14.93 billion. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. On average, equities analysts forecast that Astrazeneca Plc will post 10.25 EPS for the current fiscal year.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.